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Abstract: Macrophages are important components of the tumor-associated infiltrate and are qualified as one 
of the major players of the cancer-related inflammation. It was shown that tumor cells can either stimulate or 
mediate apoptosis of tumor-associated macrophages (TAMs). To date, there is no general agreement regarding 
the influence of TAMs and their numbers on the progression of hepatocellular carcinoma (HCC) and hepatic 
metastases (HM). To analyze the presence of TAMs and compare their numbers in intratumoral (IT) and pe-
ritumoral (PT) areas with the clinical outcome of HCC and HM patients. Biopsies from 35 HCC and 39 HM 
cases were analyzed. Clinical and follow-up data was enrolled for each case; the colorectal cancer was the origin 
of 26 HM patients. TAMs were identified by immunohistochemistry using anti-CD68 monoclonal antibody. 
The quantitative assessment was performed by determining the mean number of CD68-positive cells in IT and 
PT areas in HCC and HM. Two threshold methods were applied: threshold 1 (T1) was calculated with the use 
of (-log) Cox method; threshold 2 (T2) was considered as 1/3 TAMs number of group’s mean. For statistical 
analyses Mann-Whitney U-test, Spearman’s correlation, Cox proportional hazard and Kaplan-Meier tests were 
applied. To date, 36.12% HCC and 27.78% HM patients were alive, median survival was 5 and 17 months for 
HCC and HM, respectively (P = 0.05). We found significant two-fold decrease of TAMs numbers between IT vs. 
PT territories in both HCC and HM. A positive correlation between numbers of PT and IT TAMs was observed 
in HM group (rs = 0.48, P < 0.05) but not in HCC. The number of TAMs was not associated with any studied 
clinical factor. Univariate Cox regression analysis showed that tumor stage £ II (P = 0.01) and increased num-
ber of PT TAMs (P = 0.06, only when T2 value was applied) were associated with favorable prognosis in HCC 
(HR = 2.614 and 2.457, respectively). Univariate and multivariate Cox analyses in HM revealed favorable progno-
sis for histological grade £ G2 and one lobe tumors (P = 0.021 and 0.045; HR = 0.395 and 0.438, respectively). 
Survival analysis retained the impact of increased TAMs numbers in peritumoral areas (P = 0.03), tumor stages 
in HCC (P = 0.007), lobes’ number (P = 0.007) and histological grade (P = 0.005) on HM patients’ outcome. In 
HCC and HM the low number of TAMs in intratumoral areas was related to the tumor cell microenvironment. 
The increased peritumoral TAMs number in primary liver tumors was associated with better prognosis. (Folia 
Histochemica et Cytobiologica 2014, Vol. 52, No. 2, 112–123)
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Introduction
The hepatic tumor microenvironment expresses 
a unique cellular and molecular profile which may 
be characterized by cellular and non-cellular compo-
nents [1] with interdependent functions and reciprocal 
signaling during their involvement in the process of car-
cinogenesis [2]. Macrophages, dendritic cells, mast cells, 
cytotoxic natural killer cells, and T cells of the hepatic 
microenvironment are responsible for the development 
of innate immune responses adapted to a tolerant im-
munological status [1, 3, 4] which is regarded as procar-
cinogenic. Moreover, liver extracellular matrix (ECM) 
contains a large diversity of molecules secreted by both 
parenchymal and non-parenchymal liver cells, such as 
growth factors, proteolytic enzymes with their specific 
inhibitors, and inflammatory cytokines [1, 2] which affect 
function of both immune and non-immune cells.
Macrophages are important components of the 
tumor-associated infiltration, being considered as 
major players of the cancer-related inflammation [5]. 
Tumor-associated macrophage (TAM) population is 
heterogeneous with two major subtypes described: 
classically activated (type I or M1) and alternatively 
activated macrophages (type II or M2) [6–8]. Refer-
ring the origin of the TAMs, it was hypothesized that 
microenvironmental factors induce the differentiation 
toward one specific phenotype [8] since supplemen-
tary and intermediary phenotypes were noticed by 
some studies [9]. Macrophages’ heterogeneity, based 
on their functional plasticity [10], resulted in the com-
parison of the pro- or anti-tumor activity of TAMs to 
a “double-edges sword” [7, 11] or “Janus face” [12]. 
Recent studies sustain that TAMs represent an 
unfavorable prognostic factor in hepatocellular car-
cinoma (HCC), since the TAM-secreted molecules 
stimulate the growth and survival of HCC cells, the 
epithelial-mesenchymal transition (EMT), tumoral 
angiogenesis, ECM remodeling, and suppression of 
the anti-tumoral immunity [13, 14]. On the other hand, 
TAMs association to an improved postoperative survi-
val and their role as positive prognostic factor in HCC 
were supported by other research groups [15, 16]. In 
the studies of TAMs involvement in the development 
of hepatic metastases (HM), the most numerous were 
related to the colorectal cancer (CRC)-associated 
metastases [17–21]. Similarly to HCC, macrophages 
in HM can act against metastatic cells in a direct 
cytotoxic way or by secretion of TNF and proteases 
[22], however, TAMs can also support survival and 
differentiation of malignant cells via secretion of 
growth factors [23] or metalloproteinases [24]. 
Within this context, the objective of our study 
was a qualitative and quantitative characterization 
of TAMs in HCC vs. HM in intra- and peritumoral 
areas, followed by statistical assessment of TAMs as 
a possible prognostic factor. 
Material and methods
Patients. The retrospective study was approved by the Ethics 
Committee of the “Grigore T. Popa” University of Medicine 
and Pharmacy, Iaşi, Romania, based on the patients’ informed 
written consent for the usage of the biologic material for 
research. The study included 74 patients diagnosed with hepa-
tocellular carcinoma (HCC, 35 cases — Group 1) and hepatic 
metastases of different origins (HM, 39 cases — Group 2) 
between January 2009 and December 2011, at the ”Sf. 
Spiridon” University Hospital, Iaşi, Romania. The patients 
were surgically treated, without preoperative chemotherapy 
or radiotherapy. Within HM group the origin of the hepatic 
metastases was: colorectal cancer — 24 cases (18 colon cancer, 
6 rectal cancer), stomach — 8 cases, pancreatic — 2 cases, 
gallbladder — 1 case, duodenal — 1 case, ovarian — 1 case, 
breast — 1 case, adrenal gland cancer — 1 case. The histo-
pathological examinations were performed in the hospital’s 
pathology laboratory, where the harvested tumor fragments 
were processed into paraffin blocks using classic histological 
technique. The patients’ clinicopathological characteristics 
were summarized in Table 1 and Table 2. The median survival 
rates were 5 months for HCC and 17 months for HM cases. 
On 31st of January 2013 36.12% of HCC patients and 27.78% 
of HM patients were alive. All recorded patients’ deaths were 
associated with diagnosed cancer disease.
Immunohistochemistry. For immunohistochemical (IHC) 
study formalin fixed, paraffin-embedded (FFPE) 4 µm-thick 
tissue sections, corresponding to the areas previously exa-
mined by pathologist, were displayed on Superfrost Plus 
(Thermo Fischer Scientific, Fitchburg, WI, USA) slides. 
Sections were deparaffinized in two xylene baths 1st at 58°C 
for 30 min and 2nd at room temperature (RT) for 10 min. The 
rehydration was made in four following alcohol solutions 
(100%, 90%, 80%, and 70% EtOH) for 10 min each. For 
antigen retrieval, we used heat-induced epitope retrieval 
(HIER), by immersing the slides in a citrate buffer (pH 6.0) 
(Leica Biosystem, Newcastle Ltd, United Kingdom) at 98°C 
for 30 min. After cooling the slides at room temperature 
(RT) for 20 min the endogenous peroxidase was blocked by 
incubation with 3% hydrogen peroxide solution (RT, for 10 
min), followed by one wash with distilled water for 5 min. 
For the IHC identification of macrophages, slides were 
incubated with the primary antibody (1:1200, mouse 
anti-human CD68 monoclonal antibody, code: NCL-CD-
68-KP1, Novocastra, Leica Biosystem), overnight at 4°C. 
The immunoreaction was developed with Novolink polymer 
kit (Novocastra, Leica Biosystem) as following: incubation 
with biotinylated secondary antibody and with the enzyme, 
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respectively, for 30 min each, at RT. Between each step of 
incubation (primary and secondary antibodies, enzyme), 
slides were washed in 3 baths of phosphate-buffer saline for 
5 min each. For visualization, we used 3.3’-diaminobenzi-
dine dihydrochloride (DAB, Novocastra, Leica Biosystem) 
for 3 min — the immunopositivity was confirmed through 
the presence of a brown product. The nuclei were then 
counterstained with hematoxylin and mounted in non-aqu-
eous mounting medium. The negative control was made 
concomitantly by omitting the incubation with the primary 
antibody, and respecting all the other steps of the protocol. 
The positive control was made during the same run by using 
a tonsil tissue section.
Quantitative analysis. The quantitative assessment was 
performed, for each case, by counting the number of CD68- 
-posi tive cells in 10 microscopic fields with the highest den-
sity of macrophages, at 200 × magnification, separately for 
the intratumoral and peritumoral territories. Our method 
represented a modified variant of the semi-quantitative 
evaluation of macrophages proposed by Forssell and 
co-workers, in colon cancer [25]. The IHC evaluation was 
done independently by two histopathologists (E.R.A. and 
S.E.G.) trained in IHC interpretation, unaware of the clin-
ical outcome. On the basis of the mean number of TAMs 
of each case, we have determined the mean number of 
macrophages for each studied group, separately for intra-
tumoral (IT) and peritumoral (PT) territories. 
Statistical analysis. Statistical analysis has been performed 
using MedCalc software (MedCalc Software, Ostend, 
Belgium) and GraphPad Prism ver. 6 (GraphPad Software 
Inc., La Jolla, CA, USA). Patients’ characteristics were 
given in absolute and relative numbers or as mean values 
with standard error of the mean (SEM). Mean macrophage 
scores for each subgroup were further checked with the 
use of D’Agostino normality test. Mann-Whitney U test 
was used for statistical comparison between two variables 
whereas Kruskal-Wallis ANOVA test was utilized when 
more than two independent variables were analyzed. For 
checking the associations between variables, Spearman’s 
correlation was utilized. 
Estimation of thresholds. Two thresholds were estimated: 
research and analytical. The first threshold (T1) was calcu-
lated for TAMs using univariate Cox regressions analyses 
(-log test). Therefore, cases with lower mean score than T1 
for the respective division were considered as subgroup 1 
(or ) whereas cases with higher mean macrophages score 
were treated as subgroup 2 (or ). The second threshold 
(T2) has been additionally used in order to verify if a lower 
value compared to the average value of the group might 
offer a superior refinement of the correlation with patients’ 
survival. T2 was calculated as 1/3 of macrophages mean num-
ber for each group and territory divisions. Thus, specimens 
with lower macrophage number than T2 were marked to 
subgroup 3 (or ) whereas cases with higher number than 
Table 2. Clinicopathological characteristics of patients  
— Group 2, hepatic metastases (HM)
Variables Variable  
description
Cases
number
(%)
Age
 
 
    £ 68
    > 68
Mean ± SD;  
median,  
range (years)
67.6 ± 11.9; 
70, 35–86
 
17
22
 
 
 
43.58
56.41
Gender
    Female
    Male
 
18
21
 
46.15
53.84
Tumor stage
    Stage IV
 
TxNxM1
 
39
 
100
Histological grade
    G1
 
    G2
 
    G3
 
    G4
 
Well  
differentiated
Moderately  
differentiated
Poorly  
differentiated
Undifferentiated
 
3
 
20
 
14
 
2
 
7.69
 
51.28
 
35.89
 
5.12
Tumoral extension
    One lobe
    Many lobes
 
26
13
 
66.66
33.33
Table 1. Clinicopathological characteristics of patients  
— Group 1, hepatocellular carcinoma (HCC)
Variables Variable  
description
Cases  
number
(%)
Age
    £ 63
    > 63
Mean ± SD;  
median,  
range (years)
62.9 ± 10.7;  
64, 23–83
17
18
48.57
51.42
Gender
    Female
    Male
12
23
34.28
65.71
Tumor stage*,**
    Stage I
    Stage II
    Stage IIIa
    Stage IV
T1N0M0
T2N0M0
T3N0M0
TxNxM1
5
13
16
1
14.28
37.14
45.17
2.8
Histological grade*,**
    G1
    G2
    G3
Well  
differentiated
Moderately 
differentiated
Poorly  
differentiated
13
15
7
37.14
42.86
20.00
*pTNM and histological divisions according to [43]; **pTNM stages 
(IIIb, IIIc) and G4 were not diagnosed, therefore they were omitted
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T2 were scored to subgroup 4 (or ). Both T1 and T2 were 
further considered in survival analyses. Fisher 2 × 2 test was 
utilized for the statistical comparison between subgroups 
based on T1/T2 classification.
Survival analysis. The Cox-Mantel proportional hazard 
regression model was used to evaluate the effect of explor-
ative variables on survival of HCC and HM patients. First, 
univariate Cox regression analysis for every single variable 
was performed. Secondly, variables with a P value < 0.05 
were included into multivariate Cox regression analysis 
with a variable selection via backward elimination. All as-
sociations were presented as hazard ratios (HR) with their 
95% confidence interval (CI) and P values. Kaplan–Meier 
estimations were performed to describe survival rates. 
Results
Qualitative evaluation
Microscopic examination has revealed both in Group 1 
— HCC and in Group 2 — HM, CD68 immunoreac-
tive (CD68+) dominant population in the periphery of 
tumoral islands or nodules, at the interface with the 
normal liver parenchyma (Figures 1–4). This territory 
could be identified in all cases, being considered as the 
tumor’s invasion front. Macrophages were identified as 
either single isolated cells or in small compact groups, 
inside the tumor, being mainly disposed in the area 
corresponding to the most external 2–3 cell layers (Fig-
ures 1–4). The qualitative evaluation, based on a visual, 
subjective appreciation of macrophages’ presence did 
not reveal differences between the distribution (loca-
tion) patterns of these cells in the HCC vs. HM. 
Figure 1. Pattern of macrophages distribution in HCC: 
numerous at the border of a tumoral nodule, very few dis-
persed within tumor (immunohistochemical, IHC, detec-
tion by anti-CD68 monoclonal antibody). Objective × 20
Figure 2. IHC detection of macrophages at the interface 
between HCC and normal liver parenchyma. Objective × 40
Figure 3. Distribution pattern of macrophages in HM: nu-
merous at the border of the cancer proliferation, very few 
dispersed within tumor. IHC. Objective × 20
Figure 4. Macrophages disposed at the periphery of the 
metastatic nodule penetrating through the metastasized 
glands (colonic pseudocrypt). IHC. Objective × 40
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Table 3. Patients’ clinical data and numbers of macrophages in Group 1 — HCC
Case
number
Clinical variables Intratumoral macrophages Peritumoral macrophages
Age Tumor  
stage
Histological 
stage
Numerical profile 
(mean ± SD)
TAMs  
expression
Numerical profile 
(mean ± SD)
TAMs  
expression
T1* T2** T1& T2&&
1 61 pT3Nx G1 118.30 ± 23.22   303.90 ± 132.33  
2 63 pT2Nx G1 184.9 ± 73.40   317.80 ± 124.70  
3 68 pT3Nx G3 87.7 ± 44.71   50.20 ± 28.61  
4 54 pT1Nx G1 46.7 ± 29.90   172.00 ± 54.77  
5 48 pT3Nx G2 337.7 ± 50.78   344.80 ± 78.10  
6 59 pT3Nx G2 137.1 ± 68.82   289.20 ± 189.21  
7 57 pT3Nx G2 209.9 ± 81.09   59.30 ± 28.76  
8 72 pT1Nx G1 3.9 ± 2.46   32.00 ± 15.86  
9 57 pT3Nx G3 167.10 ± 98.92   227.70 ± 92.23  
10 58 pT2Nx G3 68.00 ± 25.15   272.60 ± 87.18  
11 58 pT2Nx G3 105.30 ± 97.32   156.10 ± 118.65  
12 74 pT3Nx G2 116.90 ± 50.35   248.30 ± 79.78  
13 51 pT3Nx G2 50.90 ± 25.28   170.90 ± 61.13  
14 83 pT2Nx G2 85.10 ± 50.34   376.50 ± 106.96  
15 65 pT2Nx G2 127.00 ± 57.42   0  
16 74 pT2Nx G1 0   253.40 ± 169.43  
17 67 pT2Nx G3 418.60 ± 137.75   578.50 ± 126.59  
18 74 pT2Nx G1 7.50 ± 7.97   76.20 ± 49.08  
19 70 pT3Nx G2 74.70 ± 25.56   318.40 ± 90.32  
20 68 pT3Nx G2 43.80 ± 12.56   58.00 ± 30.38  
21 64 pT1Nx G1 89.40 ± 16.22   134.00 ± 57.71  
22 72 pT1Nx G1 63.20 ± 33.15   195.10 ± 108.28  
23 56 pT3Nx G2 91.70 ± 11.84   247.70 ± 105.86  
24 75 pT3Nx G2 89.40 ± 23.15   52.10 ± 15.96  
25 60 pT3Nx G2 61.10 ± 20.61   329.00 ± 221.33  
26 57 pT2Nx G3 23.10 ± 13.21   226.70 ± 103.65  
27 75 pT2Nx G1 72.70 ± 23.36   613.20 ±123.69  
28 58 pT2Nx G2 0   281.50 ± 136.75  
29 58 pT1Nx G1 133.50 ± 49.91   117.20 ± 50.83  
30 71 p2NxM1# G3 112.60 ± 64.33   358.60 ± 78.14  
31 69 pT3Nx G1 121.30 ± 28.14   248.60 ± 62.96  
32 53 pT2Nx G2 71.70 ± 38.12   484.70 ± 181.19  
33 65 pT3Nx G1 7.90 ± 4.40   148.20 ± 81.24  
34 23 pT3Nx G1 75.00 ± 38.97   83.60 ± 53.57  
35 67 pT2Nx G2 98.20 ± 65.55   151.30 ± 75.47  
Mean ± SEM 100.05 ± 14.62 227.9 ± 24.81
Median,  
range
87.70,  
0–418.60
227.7, 
0–613.2
P                                                  < 0.0001
*IT Threshold 1 = 145.36; Subgroup 1 = ; Subgroup 2 =   
**IT Threshold 2 = 33.33; Subgroup 1 = ; Subgroup 2 =  
&PT Threshold 1 = 144.16; Subgroup 1 = ; Subgroup 2 =  
&&PT Threshold 2 = 75.96; Subgroup 1 = ; Subgroup 2 =  
#HCC metastases were diagnosed in bone
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Table 4. Patients’ clinical data and numbers of macrophages in Group 2 — HM
Case
number
Clinical variables Intratumoral TAMs Peritumoral TAMs
Age Tumor 
stage
Histological 
stage
Tumoral 
extension 
# of lobes
Numerical profile 
(mean ±SD)
TAMs  
expression
Numerical profile 
(mean ± SD)
TAMs  
expression
T1* T2** T1& T2&&
1 58 pT3N2M1 G2 1 48.2 ± 17.68   381.2 ± 154.67  
2 66 pT2NxM1 G3 1 56.2 ± 28.63   196.7 ± 126.22  
3 63 pT4NxM1 G4 1 39.2 ± 24.96   47.8 ± 24.06  
4 70 pT3N1M1 G3 1 79.3 ± 27.39   187.2 ± 37.67  
5 69 pT3N2M1 G2 1 150.5 ± 143.92   200.7 ± 90.29  
6 73 pT3N1M1 G2 1 233.2 ± 100.39   239.3 ± 114.79  
7 80 pT3N2M1 G2 > 1 197.5 ± 72.31   289.7 ± 110.09  
8 57 pT3N2M1 G2 1 180.6 ± 149.25   355.4 ± 151.00  
9 78 pT3N2M1 G2 > 1 217.6 ± 76.95   226 ± 67.10  
10 57 pT4N1M1 G2 1 49.2 ± 34.18   238.5 ± 83.78  
11 79 pT3NxM1 G3 1 255.4 ± 143.89   623.8 ± 173.25  
12 79 pT2bN3M1 G3 1 152.8 ± 40.97   185.1± 54.66  
13 52 pT3N2M1 G2 > 1 145 ± 31.13   208.3 ± 96.77  
14 78 pT3N3M1 G2 > 1 47.1 ± 19.54   91.3 ± 26.89  
15 55 pT3N2M1 G3 1 200.9 ± 90.50   206.3 ± 110.10  
16 62 pT3N1M1 G1 1 255.4 ± 143.89   623.8 ± 173.25  
17 65 pT3NxM1 G1 > 1 176.1± 58.87   282.5 ± 128.09  
18 82 pT3NxM1 G3 > 1 333.3 ± 95.73   397 ± 149.56  
19 72 pT3N0M1 G2 1 0   179.5 ± 69.17  
20 35 pT3N2M1 G2 1 190.7 ± 112.05   169.2 ± 72.91  
21 86 pT3N0M1 G3 1 73.1 ± 39.58   217.7 ± 78.21  
22 60 pT4N1M1 G1 1 35.2 ± 32.35   183 ± 81.01  
23 83 pT4N2M1 G3 > 1 255.4 ± 143.89   623.8 ± 173.25  
24 65 pT3N2M1 G2 1 188.8 ± 107.84   224. 6± 107.04  
25 78 pT3N2M1 G2 1 50.6 ± 24.67   84.2 ± 24.14  
26 74 pT3N2M1 G2 1 47.3 ± 24.28   194.5 ± 81.33  
27 35 pT4N1M1 G3 1 204.2 ± 107.80   242.9 ± 83.70  
28 64 pT3NXM1 G3 > 1 128.9 ± 53.97   262.9 ± 57.96  
29 48 pT3N1M1 G2 > 1 201.8 ± 116.67   410.2 ± 182.09  
30 63 pT4N1M1 G2 1 67.1 ± 57.81   197 ± 62.54  
31 72 pT3NxM1 G2 > 1 61.3 ± 30.65   398 ± 122.83  
32 76 pT2N0M1 G3 1 152.8 ± 40.97   185.1 ± 54.66  
33 61 pT3N3M1 G4 1 91.6 ± 18.31   100.5 ± 22.17  
34 72 pT4N1M1 G2 1 138.7 ± 100.73   443.1 ± 180.71  
35 68 pT4N2M1 G3 1 32.6 ± 16.16   205 ± 68.87  
36 74 pT3NxM1 G3 1 17.7 ± 17.19   106.9 ± 49.52  
37 82 pT3N1M1 G3 > 1 266.7 ± 159.46   51.7 ± 34.59  
38 70 pT3NxM2 G2 > 1 29.7 ± 12.57   218 ± 57.14  
39 75 p3N2M1 G2 > 1 150.5 ± 74.22   186.9 ± 55.94  
Mean ± SEM 133.4 ± 13.75 253.0 ± 23.01
Median,  
range
145.0,  
0–333.3
208.3,  
47.8–623.8
P                                             < 0.0001
*IT Threshold 1 = 162.29; Subgroup 1 = ; Subgroup 2 =   
**IT Threshold 2 = 44.46; Subgroup 1 = ; Subgroup 2 =  
&PT Threshold 1 = 163.00; Subgroup 1 = ; Subgroup 2 =  
&&PT Threshold 2 = 84.33; Subgroup 1 = ; Subgroup 2 = 
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Quantitative evaluation
Table 3 and 4 present the numerical values of the ma-
crophages quantification as well as clinical variables, 
in each individual case of both HCC and HM groups. 
Since TAMs scores or intratumoral subgroups did not 
pass D’Agostino normality tests, we used non-para-
metric tests for further statistical analyzes.
TAMs in hepatocellular carcinoma group 
Morphometric analysis revealed more than 2-fold 
lower number of TAMs in IT vs. PT compartment in 
HCC tumors (P < 0.0001; Table 3, Figure 5A). Thre-
shold 1 (T1) values were calculated using Cox (-log) 
test as 145.36 for IT and 144.16 for PT macrophages, 
whereas Threshold 2 (T2) values were counted as 1/3 
of mean values for subgroups as 33.33 for IT and 75.92 
for PT groups (Table 3). 
The analysis of IT macrophages by using threshold 
1 revealed the presence of 30/35 (86%) cases with 
lower score than T1. If T2 threshold was applied we 
observed a different pattern, since 6/35 (17%) cases 
showed even lower TAMs presence than T2, there-
fore T1 and T2 classifications cannot be compared 
(P < 0.0001, Fisher’s test). 
The analysis of IT macrophages in peritumoral 
territory of HCC revealed that 10/35 (28.5%) and 6/35 
(17%) cases showed lower number of TAMs when 
T1 or T2 were utilized, respectively. In this approach 
(PT in HCC), both methods of threshold determina-
tion can be compared (P = 0.39; Fisher’s test).
We found no statistical associations between 
TAMs scores and clinical data of HCC cases (data 
not shown). We did not find any correlation between 
number of macrophages in intratumoral and peri-
tumoral tissue (Figure 5B).
TAMs in hepatic metastases 
Similarly to HCC, twice more TAMs were present in 
peritumoral than in intratumoral territories of HM 
patients (P < 0.0001, Table 4; Figure 5A). T1 and 
T2 for IT area were calculated as 162.29 and 44.46, 
respectively. Within IT tissue we observed decreased 
number of TAMs for 24/39 (61.5%) or 6/39 (15.3%) 
when T1 or T2 values were applied, respectively. For 
peritumoral HM cases, with T1 and T2 set for 163 
and 84.33, respectively, we found decreased number 
of TAMs in 6/39 (15.3%) if T1 criterion was used or 
3/39 (7.7%) if T2 was applied. 
For PT in HM, T1 and T2 can be compared (P = 
0.48), whereas for IT in HM there was no agreement 
between T1 and T2 classification methods (P = 0.001, 
Fisher’s 2 × 2 test). 
Figure 5. Comparison between macrophages numbers clas-
sified by cancer origin and liver territory. A. Plot of mean 
(± SEM) number of TAMs and the results of Mann-Whit-
ney U test. B and C. correlation plots of TAMs number in 
matched HCC and HM cases with results of Spearman’s 
test. HCC — hepatocellular carcinoma, HM — hepatic me-
tastasis, IT — intratumoral, PT — peritumoral territory
Although we did not find any statistical associations 
between TAMs scores in HM and clinical data, we 
noticed a positive correlation between IT and PT sco-
res (rs = 0.48, P < 0.0001; Spearman’s test, Figure 5C). 
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Table 5. HCC and HM clinical data in relation to decreased number of macrophages in intratumoral and peritumoral 
territories
Clinicopathological factor Intratumoral territory Peritumoral territory
T1
 vs. 
T2
 vs. 
T1
 vs. 
T2
 vs. 
HCC
Age
    < 63
    ≥ 63
13 vs. 3
P = 0.6
17 vs. 2
2 vs. 14
P = 0.66
4 vs. 15
3 vs. 13
P = 0.28
7 vs. 12
1 vs. 15
P = 0.18
5 vs. 14
Tumor stage
    I–II
 
    III–IV
 
16 vs. 2
P = 0.65
14 vs. 3
 
5 vs. 13
P = 0.17
1 vs. 16
 
5 vs. 13
P = 1
5 vs. 12
 
2 vs. 16
P = 0.4
4 vs. 13
Histological grade
    G1–G2
 
    G3
 
25 vs. 3
P = 0.25
5 vs. 2
 
5 vs. 23
P = 1
1 vs. 6
 
9 vs. 19
P = 0.64
1 vs. 6
 
5 vs. 23
P = 1
1 vs. 6
HM
Age
£ 68
 
> 68
 
10 vs. 8
P = 0.2
21 vs. 7
 
3 vs. 15
P = 0.65
3 vs. 25
 
2 vs. 16
P = 0.66
4 vs. 17
 
1 vs. 17
P = 1
2 vs. 19
Histological grade
    G1–G2
 
    G3–G4
 
14 vs. 9
P = 0.2
6 vs. 10
 
3 vs. 20
P = 0.67
3 vs. 13
 
2 vs. 21
P = 0.2
4 vs. 12
 
1 vs. 22
P = 0.55
2 vs. 14
Tumor extension
    One lobe
 
    Many lobes
 
18 vs. 8
P = 0.18
6 vs. 7
 
5 vs. 21
P = 0.64
1 vs. 12
 
4 vs. 22
P = 1
2 vs. 11
 
2 vs. 24
P = 1
1 vs. 12
Furthermore, there was no difference between num-
ber of macrophages in HM or HCC when IT or PT 
territories were compared (Figure 5A).
In the explorative analysis of patients with ob-
served lower number of TAMs, either based on T1 or 
T2 scoring method, we did not observe any association 
between occurrence of low/high numbers of TAMs 
and age, TNM, histological G grade in HCC or age, 
histological G grade and number of involved lobes 
in HM (Table 5).
Analysis of prognostic factors
Univariate and multivariate Cox regression analy-
sis was used in order to find the factors which can 
influence patients’ survival or death. The summary 
analysis of all variables was presented in Table 6. In 
HCC group we observed that increasing tumor stage 
is associated with poorer prognosis (P = 0.013, HR 
2.16), which is related to × 13.6 increase of chance of 
death for patients with stages III–IV in comparison 
to HCC cases with diagnosed HCC at stages I–II. In 
liver metastasis we observed that increasing histo-
logical grades of cancer cells (G1–G2 vs. G3–G4) as 
well as increasing number of metastatic lobes (> 1) 
are the factors of poorer prognosis (P = 0.004 for 
both factors). We further included both factors in Cox 
multivariate analysis and retained their significance 
(P = 0.021 and P = 0.045 respectively). For the prog-
nostic significance of TAMs scores, we did not find 
relations in any of analyzed groups, no matter which 
threshold was applied.
Survival analysis
The possible influence of all clinical factors as well 
as TAMs scores based either on T1 or T2 classifica-
tions were assessed separately for IT and PT areas. 
We found that HCC cases with PT TAMs scores 
lower than 1/3 mean value (T2) were characterized 
by a shorter survival rate that cases with higher 
PT TAMs values (median survival 1 vs. 8 months, 
3 years survival 0% vs. 38%; Figure 6A). Other 
survival relations to TAMs were not significant. 
However, certain clinical factors had significant 
influence on HCC and HM survival rates: Stages 
I–II vs. stages IIIA–IV (median survival 28 vs. 3.5 
months, 3 years survival 42% vs. 21%, Figure 6B). 
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Table 6. Univariate and multivariate Cox regression analysis of hepatocellular carcinoma and hepatic metastases cases 
Parameters Univariate analysis Multivariate analysis
P value HR (95% CI) P value HR (95% CI)
HCC
Age 0.836 1.004 (0.961–1.049)
Histological grade  
G1–G2 vs. G3
0.316 1.382 (0.733–2.603)
Tumor stage  
≤ II vs. ≥ III
0.013 2.614 (1.209–5.410)
Intratumoral TAMs
T1  vs. 
T2  vs. 
 
0.666
0.968
 
1.269 (0.429–3.751)
1.022 (0.347–3.009)
 
 
 
 
Peritumoral TAMs
T1  vs. 
T2  vs. 
 
0.432
0.062
 
1.434 (0.582–3.532)
2.457 (0.954–6.326)
HM
Age
Histological grade
G1–G2 vs. G3–G4
0.187
 
0.004
1.025 (0.987–1.064)
 
1.701 (1.024–2.827)
 
 
0.021
 
 
0.395 (0.179–0.870)
Tumoral extension one lobe vs. multilobe 0.004 0.498 (0.225–1.101) 0.045 0.438 (0.195–0.984)
Intratumoral TAMs
T1  vs. 
T2  vs. 
 
0.966
0.973
 
0.983 (0.444–2.175)
1.018
Peritumoral TAMs
T1  vs. 
T2  vs. 
 
0.161
0.914
 
2.028
1.082
Cox analysis of  vs.  or  vs.  means that the HR and P values relate to occurrence of decrease number of TAMs
For HM we observed the poorer survival if many 
lobes were involved: one vs. multilobe involvement 
(median survival 31 vs. 5 months, 3 years survival 
29% vs. 15%, Figure 6C) or if more aggressive tumor 
cells were found in tumor biopsies: G1–G2 vs. G3–G4 
(median survival 34 vs. 3.5 months, 3 years survival 
43% vs. 6%, Figure 6D). We also noted that patients 
with HCC had worse survival outcome than HM cases 
(P = 0.0501, Figure 6E).
Discussion
Recent data presented the modulatory role of hepatic 
microenvironment both in initiation and progression 
of the primary carcinogenic process as well as in esta-
blishment of optimal conditions for metastatic colo-
nization and development [5, 12, 21, 26]. A necessary 
condition for HCC initiation and development seems 
to be the presence of activated inflammatory cells in 
the liver, through their action on signaling pathways, 
which results in enhanced cellular turnover and 
acquisition of critical modifications for the malignant 
transformation [27, 28]. 
Studies on inflammatory cells in cancer develop-
ment focused mainly on the population of tumor-in-
filtrating lymphocytes (TILs), widely reported in CRC 
[29–35], however, within liver microenvironment the 
largest physiological population of immune cells is 
represented by macrophages, namely Kupfer cells. 
Our study focused on the parallel analysis of hepatic 
TAMs in two different tumor pathologies, HCC and 
HM by evaluating the presence of macrophages in 
intra- and peritumoral territories, followed by TAMs 
quantification in respective territories. 
Regarding the method of counting TAMs and due 
to the fact that no accurate correlation between number 
of macrophages and patients’ survival could be found in 
literature, we established two threshold values. T1 was 
calculated with the use of widely used Cox method, 
however, the setting of a second threshold, T2, per-
mitted a convenient mathematical manipulation and 
had a heuristic motivation (based on the large panel of 
numerical results). Choice of T2 intended to balance 
the following two issues: 1) the use of the mean value 
of the number of macrophages does not ensure a re-
liable classification of tissues with decreased number 
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of TAMs, 2) a proper evaluation of the association of 
macrophages’ number on survival requires a reasonable 
value above the zero. We however found that our me-
thod for T2 assignment could not be applied for TAMs 
in IT territories (both in HCC and HM), which was 
probably associated with lack of normal distribution of 
the macrophages’ number in the intratumoral sections. 
Our finding of decreased presence of intratumor-
al TAMs in comparison to peritumoral territories 
both in HCC and HM are in accordance with the 
relatively few studies of TAMs in HCC [13, 15, 16] 
and HM [18, 20, 36], confirming their predominant 
presence in peritumoral area and in the vicinity of 
invasion front. Moreover, our results support the 
Figure 6. Results of Kaplan-Meier survival analyzes of chosen (P < 0.05) factors. A. HCC cases classified by higher () 
and lower () number of peritumoral macrophages. B. HCC cases divided by pTNM stages according to Benson et al. [43]. 
C. and D. Relates to survival analyses of HM cases divided by tumoral extension and histological grade of differentiation.  
E. Plot relates to survival outcome in relation to tumor disease type. P values according to Mantel-Cox log-rank test
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hypothesis of decreased macrophage infiltration 
or the inhibition of their function which resulted 
in tumor growth and metastasis [28]. Surprisingly, 
despite the diversity of the origin of primary and 
secondary liver tumors, lack of differences in TAMs 
numbers between primary vs. secondary tumors in 
respective territories could have been caused by spe-
cific characteristics of hepatic microenvironment in 
recruiting and inducing the phenotype of tumor-as-
sociated macrophages either in HCC or HM [28]. 
Consequently, the macrophage distribution pattern 
suggests that the anti-tumoral defense mechanism 
follows a similar algorithm in the liver, without any 
correlation to the tumor origin or to the primary or 
secondary tumor status [1, 11]. 
Our observation of positive correlation of TAMs 
numbers in IT and PT tumor sections of HM patients 
could be probably associated with the impact of mali-
gnant cells on hepatic macrophages. It was reported in 
HM that highly aggressive Dukes C and D malignant 
cells of CRC-origin can trigger apoptotic death of 
TAMs and monocytes by the secretion of high mobi-
lity group box 1 (HMGB1) protein [38]. On the other 
hand, malignant cells can attract TAMs by secretion 
of carcinoembryonic antigen (CEA) followed by the 
release of growth factors by enticed macrophages [21]. 
The presented study focused on the selection of 
prognostic factors for HCC and HM patients. Our re-
sults confirmed the usefulness of AJCC/UICC pTNM 
division for the prediction of the survival rate and 
hazard ratio of HCC patients [39, 40]. The influence of 
poorly/undifferentiated cells and involvement of many 
liver lobes in secondary cancer on the poorer outcome 
of HM patients has been previously reported [41]. 
Although TAMs presence in tumor microenviron-
ment was observed in many types of cancer [37], the 
value of estimating number of macrophages in tumor 
infiltrates as a prognostic factor in HCC is still un-
certain since some studies found TAMs number as a 
negative [13, 14], while other — as a positive prognosis 
factor [15, 16]. Our results suggest that the low num-
ber of PT macrophages (P = 0.07) could be assumed 
as a negative prognostic factor for HCC, which was 
further demonstrated by Kaplan-Meier analysis, 
however, we found no association with other clinical 
factors. Although this preliminary result should be 
confirmed by larger independent analyses, we wanted 
to emphasize such interesting observation. 
One of the limitations of our study is related to the 
division of mature macrophages into two subpopula-
tions: M1 and M2. M1 macrophages activated mainly 
by bacterial lipopolysaccharides and immune stimuli 
such as interferon-g (IFN-g) have anti-tumor role due 
to the elimination of tumor cells, antigen presentation 
to T cells, and synthesis of numerous proinflammatory 
cytokines [6–8]. M2 macrophages differentiate follo-
wing the contact with Th2 cells or after stimulation in 
the tumor microenvironment by cytokines (e.g. IL-4, 
IL-10, IL-13) and growth factors such as TGF-b1 [42]. 
Since we performed only basic identification for macro-
phages, future studies should assess the participation 
of M1 and M2 subpopulation of macrophages in HCC 
and HM. In this report we were not able to simulta-
neously detect CD68+, CD80+ and CD163+ cells in 
histological sections but the use of flow-cytometry to 
study isolated TAMs may provide valuable data. 
In summary, our results lead to the following two 
conclusions. (i) Low number of intratumoral TAMs 
in comparison to peritumoral territories both in HCC 
and HM may be related to negative influence of can-
cer cells. (ii) Increased TAMs number in peritumoral 
territory of hepatocellular carcinoma is associated 
with better prognosis.
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